DOvEEgene/WISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics

This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.

NCT Number	NCT02288676
Lead Sponsor	McGill University Collaborators: McGill University Health Centre/Research Institute of the McGill University Health Centre
Conditions	Ovarian Neoplasms, Endometrial Neoplasms, Endometrial Cancer, Ovarian Cancer, Screening, Safety, Reduced Mortality, Reduced Morbidity +1 more
Enrollment	1,200 participants
Start Date	2014-01
Primary Completion	2025-10 (estimated)
Study Completion	2026-10 (estimated)
Updated on ClinicalTrials.gov	2025-06-18